Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data
We observed a significantly longer median duration of oral TKI therapy (201 days) than the reported national average (< 100 days). This analysis of real-world data reveals that lengthier treatment durations for TKI + ICI combinations are feasible.
Authors
- Arash Rezazadeh Kalebasty
- Nataliya Mar (ORCID: https://orcid.org/0000-0003-2485-6201)
- Michael Forsyth
- Jorge G. Farías (ORCID: https://orcid.org/0000-0001-7660-9603)
- Yen Cao
- Ranjit K. Thirumaran (ORCID: https://orcid.org/0000-0002-7105-049X)
- David J. Benjamin (ORCID: https://orcid.org/0000-0002-2392-886X)
- Zhaohui Arter (ORCID: https://orcid.org/0000-0001-7394-7156)
Institutions
- Hoag Memorial Hospital Presbyterian (US)
- Pfizer (United States) (US)
- University of California, Irvine Medical Center (US)
Publication Details
- Journal
- Clinical Medicine Insights Oncology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1177/11795549251341877
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04